However, scientists are actively working to solve this problem
Ile 17 MAR709 experiments have tested the concurrent substitution of Gln 17 , Ala 18 , and Ala 19 from GLP-1 to Ile 17 , His 18 , and Gln 19 from GIP, and found that GLP-1 activity decreased (EC 50 : 0.022 nM0.140 nM) while that of GIP scarcely increased (EC 50 : 6.258 nM5.530 nM)
For others, symptoms linger longer
(September 2023) Tirzepatide-Induced Gastrointestinal Manifestations: A Systematic Review and Meta-Analysis (September 2023) As Semaglutides Popularity Soars, Rare but Serious Adverse Effects Are Emerging (November 2023) Glucagonlike Peptide-1 Receptor Agonists: The Good, the Bad, and the UglyBenefits for Glucose Control and Weight Loss with Side Effects of Delaying Gastric Emptying (January 2024) Diabetic gastroparesis: a disease for which long-term therapeutic benefits are difficult to obtain (May 2024) Other Possible Side Effects of Zepbound Explored Tirzepatide, the active ingredient in Zepbound, belongs to a class of drugs called GLP-1 agonists
Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human
